Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of two locations we draw on the diverse talents of a 500-strong team. More>

Myozyme® (alglucosidase alfa) Shortlisted for Prix Galien Real World Evidence Award

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that Myozyme® (alglucosidase alfa) has been shortlisted for a Prix Galien medal within the “Real World Evidence” category which recognises excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patients benefits or socio-economic gains. More>

Patients in Scotland denied prostate cancer drug - The SMC has ruled against approving Jevtana® (cabazitaxel) for advanced prostate cancer, despite recent NICE approval

Sanofi Genzyme, the specialty care global business unit of Sanofi, is disappointed with the decision by the Scottish Medicines Consortium (SMC), recommending against the use of Jevtana® (cabazitaxel) on NHS Scotland for the treatment of metastatic hormone-relapsed prostate cancer (mHRPC) and thus denying Scottish patients access to a drug that according to the National Institute for Health and Care Excellence (NICE) is a clinically-effective and cost-effective treatment that prolongs life and is valued by patients. More>

Sanofi Genzyme launches new UK nurse education programme in multiple sclerosis to help improve patient care and service delivery

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the launch of OptiMiSe, a new education programme for multiple sclerosis (MS) specialist nurses in the UK that supports patient-centric care and changes in clinical practice for improved patient outcomes. More>

Search

Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

          

 

 

'